tbuckley/cabot-search huggingface dataset:
Simultaneous quantification of ginsenoside Rg1 and its metabolites by HPLC–MS/MS: Rg1 excretion in rat bile, urine and feces
Authors: Chiyu He, Ru Feng, Yupeng Sun, Shifeng Chu, Ji Chen, Chao Ma, Jie Fu, Zhenxiong Zhao, Min Huang, Jiawen Shou, Xiaoyang Li, Yuzhu Wang, Jinfeng Hu, Yan Wang, Juntian Zhang
Journal: Acta Pharmaceutica Sinica B (2016)

Ginsenoside Rg1 (Rg1), the major effective component of ginseng, has been shown to have multiple bioactivities, but low oral bioavailability. The aim of this study was to develop a simple, sensitive and rapid high performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) method, which could be used to validate and quantify the concentrations of Rg1 and its metabolites in Sprague-Dawley rat bile, urine, and feces after oral administration (25 mg/kg). Calibration curves offered satisfactory linearity (r>0.995) within the determined ranges. Both intra-day and inter-day variances were less than 15%, and the accuracy was within 80-120%. The excretion recoveries of Rg1, ginsenoside Rh1 (Rh1), and protopanaxatriol (Ppt) in bile, urine, and feces combined were all greater than 70%. The fecal excretion recoveries of Rg1, Rh1, and Ppt were 40.11%, 22.19%, and 22.88%, respectively, whereas 6.88% of Rg1 and 0.09% of Rh1 were excreted in bile. Urinary excretion accounted for only 0.04% of Rg1. In conclusion, the observed excretion profiles for Rg1 and its metabolites after oral administration are helpful for understanding the poor oral bioavailability of Rg1 and will aid further investigations of Rg1 as a pharmacologically active component.
157P Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS Exon2 wild-type mCRC: Japanese Skin Toxicity Evaluation Protocol with Panitumumab: J-STEPP/HGCSG1001: updated analysis of anti-tumor efficacy
Authors: S. Yuki, Y. Komatsu, H. Nakatsumi, T. Muranaka, Y. Kobayashi, T. Miyagishima, N. Ehira, I. Iwanaga, H. Okuda, M. Tateyama, Y. Tsuji, K. Hatanaka, M. Nakamura, M. Kudo, H. Fukushima, H. Hisai, R. Abe, N. Sakamoto, K. Oba, Y. Sakata
Journal: Annals of Oncology (2015)
Extending Collaborative Care for Posttraumatic Mental Health
Authors: Paula P. Schnurr
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
US study adds to debate over whether e-cigarettes lead to smoking in young people
Authors: Michael McCarthy
Journal: BMJ (2016)

Older teenagers who reported using e-cigarettes were more than six times more likely to take up smoking as young adults than those who reported never using the devices, a US study has found.1

The study’s findings add to the ongoing debate over the “gateway hypothesis” that says that e-cigarette use by the young increases the likelihood that they will take up smoking as adults.

For the study, published in the journal Pediatrics , researchers sought to determine whether e-cigarette use in late adolescence was associated with smoking initiation in young adulthood, when it becomes legal to purchase cigarettes in most US jurisdictions.

The data came from the California Health Study, a prospective cohort study of adolescents who were first surveyed in grades 11 or 12 (mean age 17.4) and then again in a follow up survey around 15 months later. All …
Hepatitis A and hepatitis A virus/HIV coinfection in men who have sex with men, Warsaw, Poland, September 2008 to September 2009
Authors: M M Dabrowska, K Nazzal, A Wiercinska-Drapalo
Journal: Eurosurveillance (2011)

We describe the epidemiology and characteristics of hepatitis A among men who have sex with men (MSM)who had been hospitalised due to the infection in Warsaw, Poland, from September 2008 to September 2009. A total of 50 men were analysed; their median age was 28 years (range: 17–43). None had travelled to hepatitis A-endemic regions during the six months before hospitalisation nor had they been vaccinated against hepatitis A. Of the 50 men, 40 had been tested before hospitalisation or on admission for the presence of anti-HIV antibodies: six were coinfected with HIV.The six HIV-positive MSM were significantly older than those who were HIV negative – median age: 37 years(range: 26–43) versus 28 years (range: 17–43); p=0.02.No difference in disease severity or the duration of hospitalisation was observed, however, between the two groups. Our study underlines the need to screen MSM for hepatitis A and to vaccinate them against hepatitis A. Given the ages of the MSM in our study,we recommend that this be carried out in Poland when the MSM are aged 20–35 years. This should apply not only to MSM with multiple casual partners but also to those in monogamous relationships.
HG-12SUCCESSFUL COMBINED IMMUNOTHERAPY OF MALIGNANT GLIOMAS OF CENTRAL NERVOUS SYSTEM IN CHILDREN AND ADOLESCENTS
Authors: Igor Dolgopolov, George Chkadua, Michail Budarin, Andrey Levashov, George Mentkevich, Vidmante Daylidite
Journal: Neuro-Oncology (2016)

Nine patients were included in trial.Three pts had anaplastic astrocytoma (AA) (1 st recurrence -1 pt, 2 nd recurrence -2 pts), 4 -glioblastoma multiforme (GBM) (1 st recurrence -2 pts, 2 nd recurrence -1 pts, 3 rd recurrence -1 pt), 2diffuse brainstem glioma (BSG).The median time to the first relapse was 12 months (4 to 16), to the second one -5 months (1 to 8).The protocol of immunotherapy included combined administration of autologous dendritic cell-based vaccine (DV) and repeated intrathecal/intraventricular injections allogenic immunocompetent cells (alloIC) from interfamilial healthy incompatible donors for at least 2 years.Four of 9 pts are alive and well 82, 23, 71 and 67 months after the immunotherapy start (2 pts with GBM in the 3 rd and 2 nd relapse, 2 pts with AA in the 1 st relapse and 2 nd , respectively).Three of them are in CR proved by PET with 11 C methionine and free of any therapy for more than 15 months.One pt with 2 nd relapse of metastatic GBM is currently in SD status and on immunotherapy for 23 months.Five pts died from disease progression within 2 -4 months from the start of immunotherapy.Over the period of treatment the pts received a median of 19 (4 to 60) alloIC injections and 16 (2 to 44) DV administrations.No serious sideeffect was observed.Immunotherapy could be an attractive option for treating patients with high-grade malignant gliomas irresponsible to conventional therapy and is worthy of further investigation.
Recovery of early memories associated with reported dream imagery
Authors: S R Palombo
Journal: American Journal of Psychiatry (1984)

In recent years dreaming has been characterized as an information-processing activity that functions adaptively to match new experience with representations of past events already stored in long-term memory. Nine patients who reported dreams in psychotherapy were asked expressly if the dream imagery recalled a specific event from early in their lives. Of 50 consecutively reported dreams, 46 were associated with early events whose imagery appeared in the dream. When questioning about the past was omitted in a later series of 34 dreams, the same patients spontaneously recalled early events represented in the dream imagery only 13 times.
Introduction of an Agricultural Tobacco and Health Research Program in Canada&lt;xref ref-type="fn" rid="FN1"&gt;1&lt;/xref&gt;
Authors: B. F. Zilkey, L. S. Vickery
Journal: JNCI Journal of the National Cancer Institute (1972)

Journal Article Introduction of an Agricultural Tobacco and Health Research Program in Canada Get access B. F. Zilkey, B. F. Zilkey Canada Department of Agriculture, Tobacco Research Station, Delhi, Ontario, Canada Search for other works by this author on: Oxford Academic PubMed Google Scholar L. S. Vickery L. S. Vickery Canada Department of Agriculture, Tobacco Research Station, Delhi, Ontario, Canada Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 48, Issue 6, June 1972, Pages 1763–1764, https://doi.org/10.1093/jnci/48.6.1763 Published: 01 June 1972
Sarcoidosis
Authors: Janet M. Torpy, Alison E. Burke, Richard M. Glass
Journal: JAMA (2006)

Sarcoidosis Sarcoidosis is an inflammatory disease without a known cause and without a cure.It occurs in individuals throughout the world.Sarcoidosis usually affects the lungs, causing granulomas (inflammatory nodules).However, it can affect other organs, including the heart, liver, lymph nodes, skin, and eyes.Its symptoms vary depending on the areas of the body affected.Sometimes sarcoidosis is found incidentally, such as when a chest x-ray is taken for another reason.There are many theories about the cause of sarcoidosis, including environmental exposure, a genetic (inherited) tendency to develop sarcoidosis, viral infection, immune system overactivity, or a combination of these factors.Treatment is based on an individual' s symptoms and the degree to which involved organs are affected.The November 1, 2006, issue of JAMA includes an article about sarcoidosis.
A Preliminary Study of Nuclear Size in Tissues from Tumorous and Nontumorous Mice&lt;xref ref-type="fn" rid="fn1"&gt;2&lt;/xref&gt;
Authors: Kasten, Frederick H.
Journal: JNCI Journal of the National Cancer Institute (1955)

Journal Article A Preliminary Study of Nuclear Size in Tissues from Tumorous and Nontumorous Mice Get access Frederick H. Kasten Frederick H. Kasten Biological Station, Roswell Park Memorial Institute, Springville, N. Y. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 16, Issue 2, October 1955, Pages 579–589, https://doi.org/10.1093/jnci/16.2.579 Published: 01 October 1955 Article history Received: 27 January 1955 Published: 01 October 1955
Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer
Authors: Mark A. Preston, Julie L. Batista, Kathryn M. Wilson, Sigrid V. Carlsson, Travis Gerke, Daniel D. Sjoberg, Douglas M. Dahl, Howard D. Sesso, Adam S. Feldman, Peter H. Gann, Adam S. Kibel, Andrew J. Vickers, Lorelei A. Mucci
Journal: Journal of Clinical Oncology (2016)

Purpose Prostate-specific antigen (PSA) level in midlife predicted future prostate cancer (PCa) mortality in an unscreened Swedish population. Our purpose was to determine if a baseline PSA level during midlife predicts lethal PCa in a US population with opportunistic screening. Materials and Methods We conducted a nested case-control study among men age 40 to 59 years who gave blood before random assignment in the Physicians’ Health Study, a randomized, placebo-controlled trial of aspirin and β-carotene among 22,071 US male physicians initiated in 1982 and then transitioned into a prospective cohort with 30 years of follow-up. Baseline PSA levels were available for 234 patients with PCa and 711 age-matched controls. Seventy-one participants who developed lethal PCa were rematched to 213 controls. Conditional logistic regression was used to estimate odds ratios and the area under the receiver operating characteristic curve, with 95% CIs, of the association between baseline PSA and risk of lethal PCa. Results Median PSA among controls was 0.68, 0.88, and 0.96 ng/mL for men age 40 to 49, 50 to 54, and 55 to 59 years, respectively. Risk of lethal PCa was strongly associated with baseline PSA in midlife: odds ratios (95% CIs) comparing PSA in the &gt; 90th percentile versus less than or equal to median were 8.7 (1.0 to 78.2) at 40 to 49 years, 12.6 (1.4 to 110.4) at 50 to 54 years, and 6.9 (2.5 to 19.1) at 55 to 59 years. A total of 82%, 71%, and 86% of lethal cases occurred in men with PSA above the median at ages 40 to 49, 50 to 54, and 55 to 59 years, respectively. Conclusion PSA levels in midlife strongly predict future lethal PCa in a US cohort subject to opportunistic screening. Risk-stratified screening on the basis of midlife PSA should be considered in men age 45 to 59 years.
Sexual dysfunction in men with chronic liver disease
Authors: M C Kew
Journal: Hepatology (1988)

Men with liver disease are hypogonadal and feminised. European workers consider the liver disease itself to be the major factor but American workers blame alcohol consumption. We studied sexual dysfunction and sex hormones in three matched groups of men; controls ( n = 22), those with alcoholic liver disease ( n = 21), and those with non-alcoholic liver disease ( n = 21). Men with alcoholic liver disease had more sexual dysfunction. Testosterone and androstenedione concentrations were lower and oestradiol and dehydroepiandrosterone sulphate levels were raised in the liver disease groups. The changes were greatest in the alcoholic liver disease group. In this, the first controlled study, liver disease per se appears to cause sexual dysfunction and sex hormone changes but these changes are amplified by ethanol.
Fecal Blood Testing or Colonoscopy
Authors: Rita F. Redberg
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft- versus-host disease and extend the donor pool
Authors: JG Gribben, EC Guinan, VA Boussiotis, XY Ke, L Linsley, C Sieff, GS Gray, GJ Freeman, LM Nadler
Journal: Blood (1996)
Posaconazole versus Benznidazole for Chronic Chagas' Disease
Authors: Anis Rassi, Anis Rassi, José Antonio Marin-Neto
Journal: New England Journal of Medicine (2014)

To the Editor: In the CHAGASAZOL study, Molina et al. (May 15 issue)1 report on the use of posaconazole, as compared with benznidazole, in adults with chronic Trypanosoma cruzi infection. Significantly more patients receiving posaconazole had treatment failure than those receiving benznidazole. Benznidazole showed sustained trypanocidal activity in 94% of patients who completed treatment and follow-up. The major problem was discontinuation of benznidazole because of allergic dermatitis (in 19% of patients). In order to improve the side-effect profile of benznidazole, we have adopted the following strategies. First, we avoid the use of a daily dose of more than 300 mg, which in our patients seemed to be the cutoff for an increased incidence of side effects. Since the recommended dose of benznidazole for adults is 5 mg per kilogram of body weight per day for 60 days, patients weighing more than 60 kg would typically receive more than 300 mg daily. So in such patients, we administer a fixed dose of 300 mg per day for a total number of days that is equivalent to their weight.2 Second, in patients in whom mild-to-moderate allergic dermatitis develops, we administer low-dose systemic glucocorticoids (20 mg per day of oral prednisone or its equivalent for 10 days, followed by 10 mg per day for 10 more days) without interrupting benznidazole therapy.2,3 In a series of 35 patients who had discontinued benznidazole because of severe dermatitis but still wanted to be treated, we reinitiated benznidazole along with prednisone, with a prednisone dose of 20 mg per day for the first 14 days, followed by 10 mg per day during the remaining days of treatment. With this regimen, 72% of the patients completed the full course of therapy with little or no dermatitis. Anis Rassi, M.D. Anis Rassi, Jr., M.D., Ph.D.
Interleukin-4 (IL-4) and IL-13 bind to a shared heterodimeric complex on endothelial cells mediating vascular cell adhesion molecule-1 induction in the absence of the common gamma chain
Authors: B Schnyder, S Lugli, N Feng, H Etter, RA Lutz, B Ryffel, K Sugamura, H Wunderli- Allenspach, R Moser
Journal: Blood (1996)
Mammary Carcinogenesis by 3-Methylcholanthrene. III. Induction of Mammary Carcinoma and Milk Secretion in Male Rats Bearing Ovarian Grafts&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: T L DAO, M J GREINER
Journal: JNCI Journal of the National Cancer Institute (1961)
Effect of Dietary Fat, Antiestrogen, and Antiprolactin on the Development of Mammary Tumors in Rats2
Authors: Po-Chuen Chan, Leonard A. Cohen
Journal: JNCI Journal of the National Cancer Institute (1974)

Journal Article Effect of Dietary Fat, Antiestrogen, and Antiprolactin on the Development of Mammary Tumors in Rats Get access Po-Chuen Chan, Po-Chuen Chan Search for other works by this author on: Oxford Academic PubMed Google Scholar Leonard A. Cohen Leonard A. Cohen Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 52, Issue 1, January 1974, Pages 25–30, https://doi.org/10.1093/jnci/52.1.25 Published: 01 January 1974 Article history Received: 31 October 1972 Revision received: 10 August 1973 Accepted: 12 September 1973 Published: 01 January 1974
LG-10GENETIC ALTERATIONS IN UNCOMMON LOW-GRADE NEUROEPITHELIAL TUMORS: BRAF, FGFR1, AND MYB MUTATIONS OCCUR AT HIGH FREQUENCY AND ALIGN WITH MORPHOLOGY
Authors: Ibrahim Qaddoumi, Wilda Orisme, Ji Wen, Teresa Santiago, James Dalton, Bo Tang, Kelly Haupfear, Chandanamali Punchihewa, John Easton, Sheila Shurtleff, Amar Gajjar, Frederick Boop, Paul Klimo, Suzanne Baker, Jinghui Zhang, Gang Wu, James Downing, Ruth Tatevossian, David Ellison
Journal: Neuro-Oncology (2016)
Utilization of prepaid services by patients with psychiatric diagnoses
Authors: D T Fullerton, F N Lohrenz, G R Nyca
Journal: American Journal of Psychiatry (1976)

The authors document and discuss the utilization of psychiatric services in a rural group practice before and after the institution of a prepaid health plan. They found that the utilization of psychiatric services increased dramatically during the first year of the plan's operation. The increase in outpatient utilization continued throughout the 3 years studied, but inpatient utilization decreased after the first year and later reached a level lower than that seen before the plan was instituted. One possible reason for the decline in inpatient utilization is that increased outpatient care prevents hospitalization.
Cerebral penetration of gefitinib in patients with lung adenocarcinoma.
Authors: M. Wang, Z. Jing, C. Minjiang
Journal: Journal of Clinical Oncology (2011)

7608 Background: Central nervous system (CNS) metastases are usually associated with poor prognosis in the patients with non-small cell lung cancer (NSCLC). And in this situation the efficiency of chemotherapy is very low because of blood brain barrier. Recently there are many studies showed that epidermal growth factor receptor tyrosine kinase inhibitors such as gefitinib or erlotinib, have a significant high response rate and disease control rate in patients with brain metastases and might be considered as an initial treatment in these patients. But there were only few case reports on cerebrospinal fluid (CSF) penetration of gefitinib. So we investigated the CSF concentration of gefitinib in Chinese patients with NSCLC. Methods: This study was a perspective design and 22 patients were enrolled into this study. Cerebrospinal fluid (CSF) and serum samples were collected at the same time and analyzed for gefitinib concentration by high performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS). Results: The mean serum concentration of gefitinib was 491.8±184.2ng/ml, the mean CSF concentration of gefitinib was 6.2±4.6ng/ml, and the mean ratio of CSF concentration to serum concentration was 1.30±0.7%. Gender, age, smoking, performance status, irradiation therapy and chemotherapy line were not associated with higher gefitinib concentration both in plasma and CSF. While the CSF gefitinib penetration percentage in patients with CNS metastases was higher than patients without CNS metastases and the difference had statistic significance (1.5% vs 0.9%, P=0.010). Conclusions: Gefitinib penetration to CSF was low and patients with CNS metastases had higher CNS penetration of gefitinib. Because of the inadequate CNS drug exposure, patients with CNS metastases maybe benefit from increasing gefitinib dose.
Virus of Avian Erythromyeloblastic Leukosis. VII. Thermal Stability of Virus Infectivity; of the Virus Particle; and of the Enzyme Dephosphorylating Adenosinetriphosphate&lt;xref ref-type="fn" rid="fn1"&gt;2&lt;/xref&gt;
Authors: Edward A. Eckert, Irving Green, D. G. Sharp, Dorothy Beard, J. W. Beard
Journal: JNCI Journal of the National Cancer Institute (1955)

Virus of Avian Erythromyeloblastic Leukosis. VII. Thermal Stability of Virus Infectivity; of the Virus Particle; and of the Enzyme Dephosphorylating Adenosinetriphosphate Get access Edward A. Eckert, Edward A. Eckert Department of Surgery, Duke University School of Medicine, Durham, N.C. Search for other works by this author on: Oxford Academic PubMed Google Scholar Irving Green, Irving Green Department of Surgery, Duke University School of Medicine, Durham, N.C. Search for other works by this author on: Oxford Academic PubMed Google Scholar D. G. Sharp, D. G. Sharp Department of Surgery, Duke University School of Medicine, Durham, N.C. Search for other works by this author on: Oxford Academic PubMed Google Scholar Dorothy Beard, Dorothy Beard Department of Surgery, Duke University School of Medicine, Durham, N.C. Search for other works by this author on: Oxford Academic PubMed Google Scholar J. W. Beard J. W. Beard Department of Surgery, Duke University School of Medicine, Durham, N.C. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 16, Issue 1, August 1955, Pages 153–161, https://doi.org/10.1093/jnci/16.1.153 Published: 01 August 1955 Article history Received: 03 February 1955 Published: 01 August 1955